Altana denies delay of Daxas launch

Germany's Altana is denying rumors that it is planning to delay the US launch of its respiratory drug Daxas. Its stock has been hit by talk of a delay. The drug, which has been tapped as a potential blockbuster, is currently in a Phase III US trial. European regulators are considering Altana's marketing application.

- read this story from AFX for more

Suggested Articles

Rachel Humphrey, M.D., who joined CytomX as chief medical officer after heading immuno-oncology at AstraZeneca and Eli Lilly, has made her exit.

Scientists have discovered a scorpion toxin could inspire treatments to block the inflammation that triggers chronic pain.

The phase 2 success keeps Hal Barron’s group on track to file for approval in multiple myeloma by the end of the year.